focus -WSS

focus

author：leisure time 2025-10-01 13:58:31 - browse：677

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： STAT Virtual Event: How to Increase Diversity in Clinical Trials

focus

knowledge

WSS

What is artificial intelligence? Experts weigh in

Shingles, which affected Dianne Feinstein, is on the rise

'The View' co

Covid vaccines: Private market messier than government rollout

Hey, doctors: Don't be no

FDA advisers vote against ALS treatment from BrainStorm

focus

focus

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Sudafed saga points to U.S. issues with evaluating older drugs

23andMe had bad news about my health. I wish a person had delivered it

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

At least 13 dead in Texas as scorching temps continue

Shingles, which affected Dianne Feinstein, is on the rise

What does generative AI mean for health care? We asked experts

The biotech scorecard for the 2nd quarter: 12 industry events to watch

Jerome Adams on the need for new antivirals for Covid

Data show record exodus of life scientists from academia

entertainment

After a drawn out lobbying fight, ARPA

Would Medicare drug price negotiations stall in a shutdown?

Kaiser Permanente unions announce official strike date

How the Dana

FDA advisers vote against ALS treatment from BrainStorm

It's time to take a new tack for treating Alzheimer's

focus

Wikipedia

knowledge

knowledge